Zanamivir (Relenza): Uses, Dosage, Side Effects
Comprehensive guide to Zanamivir (Relenza): uses, dosage, side effects, and precautions for treating and preventing influenza.
Zanamivir, sold under the brand name Relenza, is an antiviral medication specifically designed to treat and prevent infections caused by influenza A and B viruses. Administered via oral inhalation using the Diskhaler device, it belongs to the class of neuraminidase inhibitors, which block the enzyme necessary for viral replication. This guide covers its uses, how it works, dosage instructions, potential side effects, precautions, and more, drawing from authoritative medical sources.
About Zanamivir
Zanamivir is indicated for the treatment of uncomplicated acute illness due to influenza A and B viruses in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days. It reduces the duration of flu symptoms by approximately 1 to 2 days when started early and can prevent influenza in certain settings. Unlike antibiotics, zanamivir targets viral infections and does not work against bacterial illnesses or the common cold. It is not a substitute for annual flu vaccination, which remains the primary prevention method.
The medication is particularly recommended for at-risk groups, including adults and children with chronic conditions, but must be used cautiously in those with respiratory issues due to the risk of bronchospasm. Relenza is supplied as 5 mg blisters in Rotadisks, compatible with the provided Diskhaler inhaler.
Key Facts
- Medicine name: Zanamivir (Relenza)
- Type of medicine: Antiviral neuraminidase inhibitor
- Used for: Treatment and prevention of influenza A and B
- Available as: Inhalation powder (5 mg per blister)
- Age suitability: 7 years and older
About Influenza
Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza A or B viruses. It spreads through droplets from coughing, sneezing, or talking, leading to outbreaks especially during winter months. Symptoms typically include sudden fever, cough, sore throat, body aches, fatigue, headache, and nasal congestion, lasting 3-7 days in uncomplicated cases. Complications like pneumonia can occur, particularly in high-risk groups such as the elderly, young children, pregnant individuals, and those with chronic diseases.
While most recover without treatment, antivirals like zanamivir can shorten symptom duration and reduce severity if initiated within 48 hours of onset. Early diagnosis relies on clinical symptoms during flu season, as lab tests are often impractical.
How Zanamivir Works
Zanamivir inhibits the influenza virus neuraminidase enzyme, which is essential for releasing new virus particles from infected cells. By blocking this enzyme, zanamivir prevents viral spread in the respiratory tract, allowing the immune system to combat the infection more effectively. It is active against all neuraminidase subtypes (N1 to N9) and reduces symptom alleviation time by 1-2 days in influenza-positive patients.
Administered directly to the lungs via inhalation, zanamivir achieves high local concentrations in the respiratory tract with minimal systemic absorption, reducing some side effects but increasing risks for those with airway diseases.
Dosage
Relenza is for oral inhalation only using the Diskhaler device. Treatment must begin within 2 days of symptom onset for optimal efficacy.
Treatment of Influenza
Adults and adolescents aged 13 years and older: 10 mg (two inhalations) twice daily for 5 days.
Children aged 5 to 12 years: Same as adults, 10 mg twice daily for 5 days.
Prevention of Influenza
- Adults and adolescents: 10 mg once daily for 10 days (community outbreak) or 28 days (household exposure).
- Children aged 5-12 years: 10 mg once daily for the same durations.
No dose adjustment is needed for renal or hepatic impairment, but use is not recommended under 5 years or in patients unable to use the inhaler properly.
| Indication | Age Group | Dosage | Duration |
|---|---|---|---|
| Treatment | 7+ years | 10 mg (2 inhalations) BID | 5 days |
| Prevention (household) | 5+ years | 10 mg (2 inhalations) QD | 10 days |
| Prevention (community) | 5+ years | 10 mg (2 inhalations) QD | 28 days |
Cautions
Zanamivir can cause bronchospasm, especially in patients with asthma or COPD. Discontinue immediately if respiratory decline occurs and seek medical help. Monitor those without prior airway disease, as cases have been reported post-marketing. Avoid in patients with severe respiratory conditions unless benefits outweigh risks. Not recommended during pregnancy or breastfeeding due to limited data; use only if essential.
- Contraindicated in hypersensitivity to zanamivir or milk proteins (excipient).
- May mask bacterial infections; monitor for secondary complications.
- Potential for neuropsychiatric events (rare); report behavioral changes.
How to Use the Inhaler
- Load a Rotadisk into the Diskhaler.
- Pierce one blister by pressing buttons.
- Exhale fully away from the device.
- Place mouthpiece in mouth and inhale deeply and steadily.
- Hold breath for a few seconds, then exhale.
- Repeat for second blister if required.
- Keep device clean and dry.
Patients unable to inhale forcefully should not use Relenza; consider alternatives like oral oseltamivir.
Side Effects
Common side effects include cough, sinusitis, dizziness, and musculoskeletal pain, occurring at similar rates to placebo. Serious risks involve bronchospasm (wheezing, dyspnea), allergic reactions (rash, swelling), and rare neurologic effects.
| Common (>1/100) | Serious (Rare) |
|---|---|
| Cough (17-18%) Sinusitis Dizziness Muscle pain | Bronchospasm Anaphylaxis Neuropsychiatric events Decline in respiratory function |
Report severe symptoms like difficulty breathing, swelling, or persistent fever to a healthcare provider immediately.
Interactions
No significant drug interactions are known, as zanamivir has low systemic exposure. However, concurrent live attenuated influenza vaccine should be avoided for at least 48 hours after Relenza, and vice versa for 2 weeks, due to potential vaccine inactivation.
Overdose and Missed Dose
Limited data on overdose; treat symptomatically. If a dose is missed, take it as soon as remembered unless near the next dose. Do not double up.
Pregnancy and Breastfeeding
Animal studies show no adverse effects, but human data are limited (Category B). Use only if clearly needed. It is unknown if zanamivir passes into breast milk; weigh risks.
Storage
Store at room temperature (20-25°C), away from moisture and heat. Keep Rotadisks sealed until use.
Frequently Asked Questions (FAQs)
Q: Who should use Zanamivir?
A: Adults and children 7+ years with uncomplicated flu symptoms starting within 48 hours, or for prevention in at-risk groups.
Q: Can Zanamivir be used for colds?
A: No, it is specific to influenza viruses, not colds or bacterial infections.
Q: Is Relenza safe for asthmatics?
A: Use with caution; risk of bronchospasm. Have a bronchodilator available.
Q: Does it replace the flu vaccine?
A: No, vaccination is preferred; Relenza treats active infections.
Q: How quickly does it work?
A: Shortens symptoms by 1-2 days if started early.
References
- Zanamivir: an influenza virus neuraminidase inhibitor — PubMed/NCBI. 2005-06-01. https://pubmed.ncbi.nlm.nih.gov/15918777/
- Zanamivir (Relenza) — Medinfo. Accessed 2026. https://www.medinfo.com/drugs/zanamivir.html
- Relenza (zanamivir) – Uses, Side Effects, and More — WebMD. Accessed 2026. https://www.webmd.com/drugs/2/drug-17483/relenza-diskhaler-inhalation/details
- Zanamivir (Relenza): Uses & Side Effects — Cleveland Clinic. Accessed 2026. https://my.clevelandclinic.org/health/drugs/18333-zanamivir-oral-inhalation-powder
- RELENZA (zanamivir) Prescribing Information — FDA. 2023-01-01. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021036s034lbl.pdf
- Relenza (zanamivir inhalation powder) Prescribing Information — GSK. Accessed 2026. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Relenza/pdf/RELENZA-PI-PIL-IFU.PDF
- Zanamivir (inhalation route) — Mayo Clinic. Accessed 2026. https://www.mayoclinic.org/drugs-supplements/zanamivir-inhalation-route/description/drg-20066752
Similar Articles
Read full bio of Sneha Tete
